Equities

Clinigen Group PLC

Clinigen Group PLC

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,034.00
  • Today's Change-1.00 / -0.10%
  • Shares traded291.56k
  • 1 Year change29.17%
  • Beta0.8053
Data delayed at least 20 minutes, as of Jan 16 2018 16:35 GMT.
More ▼

Key statistics

On Tuesday, Clinigen Group PLC (CLIN:LSE) closed at 1,034.00, -12.89% below its 52-week high of 1,187.00, set on Nov 01, 2017.
52-week range
Today
751.50Mar 23 20171,187.00Nov 01 2017
Markit short selling activity
Low
Med
High
Open1,034.00
High1,047.00
Low1,022.00
Bid--
Offer1,200.00
Previous close1,035.00
Average volume608.26k
Shares outstanding122.29m
Free float110.46m
P/E (TTM)317.58
Market cap1.27bn GBP
EPS (TTM)0.0326
GBP
Annual div (ADY)5.00
GBX
Annual div yield (ADY)0.48%
Div ex-dateNov 09 2017
Div pay-dateDec 01 2017
Data delayed at least 20 minutes, as of Jan 16 2018 16:35 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on Clinigen Group PLC shares was Buy at 1,090.00 on 03 Oct 2017Read the full article
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.